CLBS Caladrius Biosciences, Inc.

4.95
+0  (2%)
Previous Close 4.87
Open 4.86
Price To book 0.00
Market Cap N/A
Shares 0
Volume 48,170
Short Ratio 0.00
Av. Daily Volume 115,847

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment of first cohort completed September 2016. Second cohort commenced enrollment October 2016. Interim analysis due late 2017 or early 2018.
CLBS03
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
CLBS20
Metastatic melanoma

Latest News

  1. Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Caladrius Biosciences, Inc. - CLBS
  2. Caladrius Biosciences to Hold 2017 Annual Stockholder Meeting on May 16
  3. Caladrius Biosciences to Participate at Upcoming April Conferences
  4. Caladrius Biosciences Announces Addition of Four Clinical Sites, Including Joslin Diabetes Center, for the Ongoing Phase 2 Study of CLBS03 in T1D
  5. ETFs with exposure to Caladrius Biosciences, Inc. : March 27, 2017
  6. Caladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  7. Company News for March 20, 2017
  8. Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results
  9. Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million
  10. Caladrius Biosciences to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 17, 2017 at 8:30 am Eastern Time
  11. Caladrius Biosciences to Present at Upcoming March Conferences
  12. With $12.2M In CIRM Funding, Caladrius Biosciences Inc (CLBS) Takes On Autoimmune Disease In Type I Diabetes
  13. Caladrius Biosciences Awarded $12.2 Million Grant from CIRM in Support of Phase 2 Clinical Trial of CLBS03 to Treat Type 1 Diabetes
  14. While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever
  15. Caladrius Biosciences to Present at Upcoming February Conferences
  16. ETFs with exposure to Caladrius Biosciences, Inc. : December 27, 2016
  17. Three Companies Set To Benefit From The 21st Century Cures Act: Who And Why